Document:

EX-10.1

 Exhibit 10.1 

SEPARATION AGREEMENT AND RELEASE 

This Separation Agreement and Release (“Agreement”) is made between Orchard Therapeutics plc (the “Parent”), Orchard
Therapeutics North America, a California corporation (the “U.S. Subsidiary”) and Mark Rothera (the “Executive”). The Parent, the U.S. Subsidiary and their respective subsidiaries and other affiliates are collectively referred to
herein as the “Company,” and the obligations of the Company set forth in this Agreement may be discharged by any entity within that definition. The Parent, the U.S. Subsidiary and the Executive are collectively referred to as the
“Parties.” 
 WHEREAS, the Parties entered into an Employment Agreement signed by the Executive on May 24, 2019 (the
“Employment Agreement”) which replaced and superseded a prior employment agreement between the Executive and the U.S. Subsidiary, dated June 12, 2017 (the “Prior Employment Agreement”); 

WHEREAS, pursuant to the Employment Agreement, the Company agreed to provide the Executive with certain severance pay and benefits (the
“Severance Benefits”) in the event of certain cessations of employment, subject to, among other things, the Executive entering into, not revoking and complying with a Separation Agreement and Release; 

WHEREAS, the Board of Directors of the Parent (the “Board”) appreciates the Executive’s contributions to the Company;

 WHEREAS, the Company and the Executive have agreed to treat the ending of the Executive’s employment with the Company as
ending pursuant to Section 3(d) of the Employment Agreement effective March 17, 2020 (the “Date of Termination”); 

WHEREAS, this Agreement is the Separation Agreement and Release referred to in the Employment Agreement; 

WHEREAS, in exchange for, among other things, the Executive entering into and not revoking this Agreement and fully complying with the
Continuing Obligations (as defined below), the Company shall provide the Executive with the Severance Benefits as described in Section 3 of this Agreement and the partial accelerated vesting and Extended Exercise Period with respect to the
Executive’s equity awards as described in Section 4 of this Agreement; and 
 WHEREAS, the payments and benefits set forth
in this Agreement are the exclusive payments and benefits to be paid or provided to the Executive in connection with the ending of the Executive’s employment. By entering into this Agreement, the Executive acknowledges and agrees that he is not
entitled to any other severance pay, benefits or equity rights including without limitation pursuant to any severance plan, program or arrangement. 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereby
agree as follows: 

  
 1 

 1. Resignation from Positions. The Executive confirms his resignation as of the Date of
Termination as an officer of the Company as well as from any other director or officer positions he holds with the Parent, the U.S. Subsidiary or any of the foregoing’s subsidiaries or affiliates. The Executive agrees to execute any documents
reasonably requested by the Parent, the U.S. Subsidiary or any of their controlled entities in order to effectuate such resignations. 
 2. Accrued
Obligations. On the Date of Termination (or such later date not to exceed 30 days after the Date of Termination with respect to (ii) below), the Executive shall be paid in full for: (i) any Base Salary (as defined in the Employment
Agreement) earned through the Date of Termination, (ii) unpaid expense reimbursements (subject to, and in accordance with, Section 2(c) of the Employment Agreement), and (iii) 19.5 days of unused vacation that accrued through the Date of
Termination. In addition, the Executive will be paid or provided any vested benefits the Executive may have under any employee benefit plan of the Company through the Date of Termination, which vested benefits shall be paid and/or provided in
accordance with the terms of such employee benefit plans. 
 3. Severance Benefits. In exchange for, among other things, the Executive signing,
not revoking and complying with the terms of this Agreement: 
 (a) the Company shall pay the Executive an amount equal to 12
months of the Executive’s Base Salary (the “Severance Amount”). The Severance Amount shall be paid out in substantially equal installments in accordance with the Company’s payroll practice over 12 months commencing on the
Company’s next practicable regular payroll date after the Effective Date of this Agreement (as defined below); provided that the initial payment shall include a catch-up payment to cover amounts
retroactive to the day immediately following the Date of Termination; and 
 (b) in lieu of the Company paying a pro-rata amount of the Executive’s Target Bonus (as defined in the Employment Agreement) based on the Executive’s actual performance in 2020, as contemplated by Section 5(c) of the Employment
Agreement, the Company shall pay the Executive a pro-rata bonus on the next practicable regular payroll date after the Effective Date of this Agreement based on 100% achievement of applicable metrics from
January 1, 2020 through the Date of Termination (the “Pro-Rata Bonus”); provided that, and for the avoidance of doubt, the Pro-Rata Bonus will be a
portion of $271,650, which represents the Executive’s full 50% Target Bonus amount based on his 2020 Base Salary of $543,300; and 

(c) if the Executive was participating in the Company’s group health plan immediately prior to the Date of Termination and
elects COBRA health continuation, then the Company shall pay the monthly employer COBRA premium for the same level of group health coverage as in effect for the Executive on the Date of Termination until the earliest of the following: (i) the
12 month anniversary of the Date of Termination; (ii) the Executive’s eligibility for group health coverage through other employment; or (iii) the end of the Executive’s eligibility under COBRA for continuation coverage for
health care. Notwithstanding the foregoing, if the Company determines at any time that its payments pursuant to this paragraph may be taxable income to the Executive, it may convert such payments to payroll payments directly to the Executive on the
Company’s regular payroll dates, which shall be subject to tax-related deductions and withholdings; 

  
 2 

 (d) in lieu of the Company paying up to $20,000 to an outplacement services
provider for the purposes of providing outplacement services to the Executive, the Company will directly pay the Executive an amount equal to $15,000, which shall be paid in a lump sum at the same time that the first payment of the Severance Amount
is made; 
 (e) the Company will reimburse the Executive for legal fees associated with his counsel’s review of this
Agreement and related documents in an amount not to exceed $5,000; and 
 (f) the Company will reimburse the Executive for
fees associated with his tax professional’s assistance with his 2019 and 2020 tax returns in an amount not to exceed $7,500, net of applicable taxes, with respect to each of the 2019 and 2020 tax year. 

If the Executive has signed this Agreement and it has become irrevocable, and within three (3) months after the Date of Termination a Change in Control
of the Parent occurs (as defined in the Employment Agreement), any payments or benefits payable before the Change in Control of the Parent will continue to be treated as payable under this Section 3, and any payments or benefits payable after
the Change in Control of the Parent will be paid pursuant to Section 6(a) of the Employment Agreement, provided that the payments and benefits to be paid pursuant to Section 6(a) of the Employment Agreement will be decreased by the amount
of any previously paid payments or benefits pursuant to Section 3 of this Agreement. In no event may there be duplication of payments or benefits under this Section 3 and Section 6(a) of the Employment Agreement. 

4. Equity. The equity awards held by the Executive shall be governed by the terms and conditions of the Company’s applicable
equity incentive plan(s) and the applicable award agreement(s) governing the terms of such equity awards held by the Executive (collectively, the “Equity Documents”); provided, however, that if the Executive signs, does not revoke and
complies with this Agreement, then notwithstanding anything to the contrary in the Equity Documents: 
 (a) all time-based
stock options held by the Executive and scheduled to vest in the 12 month period following the Date of Termination shall immediately accelerate and become fully exercisable as of the later of (i) the Date of Termination or (ii) the
effective date of the Separation Agreement and Release (the “Accelerated Vesting Date”); provided that no additional vesting of equity awards shall occur during the period between the Date of Termination and the Accelerated Vesting Date;
provided further, and for the avoidance of doubt, no equity awards subject to performance-based vesting shall be affected by this Section 4(a); and 

(b) the Company shall extend the exercise period with respect to the Executive’s vested stock options as of the
Accelerated Vesting Date until the earlier of (i) the original expiration date for such vested stock options as provided in the applicable Equity Documents, or (ii) 12 months after the Date of Termination (the “Extended Exercise Period”).

  
 3 

 Although the Executive shall cease vesting in his equity awards on the Date of Termination, except as
otherwise set forth in this Section 4, and the exercise period with respect to any vested stock options shall commence on the Date of Termination, the termination or forfeiture of the unvested portion of the Executive’s equity awards
(including, for avoidance of doubt, equity awards subject to performance-based vesting) that would otherwise occur on the Date of Termination will be delayed to the extent necessary to effectuate the terms of this Agreement and Section 6(a)(ii)
of the Employment Agreement in the event that a Change in Control of the Parent occurs within three (3) months following the Date of Termination. If a Change in Control of the Parent does not occur within (3) months following the Date of
Termination, then the unvested portion of the Executive’s equity awards that would otherwise have terminated or been forfeited on the Date of Termination shall terminate or be forfeited on the three (3) month anniversary of the Date of
Termination. 
 5. General Release. In consideration for, among other terms, the Severance Benefits set forth in Section 3 of this
Agreement, to which the Executive acknowledges he would not otherwise be entitled, the Executive irrevocably and unconditionally releases and forever discharges the U.S. Subsidiary, the Parent, all of the U.S. Subsidiary’s and the Parent’s
respective affiliated and related entities, each of the foregoing entities’ respective predecessors, successors and assigns, employee benefit plans and the fiduciaries of such plans, and the current and former officers, directors, shareholders,
employees, attorneys, accountants, fiduciaries and agents of each of the foregoing in their official and personal capacities (collectively referred to as the “Releasees”) generally from all claims, demands, debts, damages and liabilities
of every name and nature, known or unknown, that, as of the date when the Executive signs this Agreement, he has, ever had, now claims to have or ever claimed to have had against any or all of the Releasees (“Claims”). This release
includes, without limitation, the complete waiver and release of all Claims: arising in connection with or under the Employment Agreement and the Prior Employment Agreement or any other agreement between the Executive and any of the Releasees; of
wrongful termination of employment, whether in contract or tort; of intentional, reckless or negligent infliction of emotional distress; of breach of any express or implied covenant of employment, including the covenant of good faith and fair
dealing; of interference with contractual or advantageous relations, whether prospective or existing; deceit or misrepresentation; of discrimination or retaliation under federal, state, local or foreign law, including, without limitation, Title VII
of the Civil Rights Act of 1964, 42 U.S.C. § 2000e et seq., as amended, the Americans with Disabilities Act, 42 U.S.C. § 12101 et seq., the Age Discrimination in Employment Act, 29 U.S.C. § 621 et seq., and Chapter 151B of the
Massachusetts General Laws; under any federal, state, local or foreign statute, rule, ordinance or regulation; of breach of contract, promissory estoppel or detrimental reliance; of violation of public policy; for wages, bonuses, incentive
compensation, vacation pay or any other compensation or benefits, whether under the Massachusetts Wage Act, M.G.L. c. 149, §§148- 150C, or otherwise; for severance allowances or entitlements; for
fraud, slander, libel, defamation, disparagement, personal injury, negligence, compensatory or punitive damages, or any other Claim for damages or injury of any kind whatsoever; and for monetary recovery,

  
 4 

 
injunctive relief, attorneys’ fees, experts’ fees, medical fees or expenses, costs and disbursements. The Executive understands that this general release of Claims includes, without
limitation, any and all Claims related to the Executive’s employment by the U.S. Subsidiary or the Parent (including without limitation, any Claims against the U.S. Subsidiary or the Parent in respect of any stock-based awards of any kind) and
the termination of his employment, and all Claims in his capacity as a stockholder of the Parent or the U.S. Subsidiary arising up to and through the date that the Executive signs this Agreement. The Executive understands that this general release
does not extend to any rights or claims that may arise out of acts or events that occur after the date on which the Executive signs this Agreement. The Executive represents that he has not assigned to any third party and has not filed with any
agency or court any Claim released by this Agreement. This release does not affect the Executive’s rights or obligations under this Agreement, nor shall it affect the Executive’s rights, if any, to vested accrued benefits pursuant to the
Company’s employee benefits plan(s), or his rights to indemnification by the Company pursuant to the Company’s organizational documents or any indemnification agreement between the Executive and the Company, or coverage, if any, under
applicable directors’ and officers’ insurance policies. 
 6. Return of Property. No later than the Date of Termination, the
Executive shall be required to return all Company property, including, without limitation, computer equipment, software, keys and access cards, credit cards, files and any documents (including computerized data and any copies made of any
computerized data or software) containing information concerning the Company, its business or its business relationships (“Company Property”). If necessary, the Executive may make arrangements with the Company’s Human Resources team
to promptly return such Company Property. By signing below, the Executive acknowledges that all such Company Property has been returned to the Company. After returning all Company Property, the Executive commits to deleting and finally purging any
duplicates of files or documents that may contain Company or customer information from any non-Company computer or other device that remains the Executive’s property after the Date of Termination. The
obligations contained in this Section 6 are supplemental to, and not in lieu of, any return of property obligations the Executive has pursuant to the Restrictive Covenants Agreement (as defined below). Notwithstanding the Executive’s
obligation to return his Company phone to the Company, the Company shall permit the Executive to port the telephone number associated with his Company phone to his new personal line. 

7. Communications Regarding Departure. The Executive agrees that he will not communicate about his departure with anyone until after the Chairman
of the Board has made a formal written announcement about the Executive’s departure through an email communication (the “Company Announcement”); provided that the Executive may communicate with his tax advisors, attorneys, and
immediate family members about his departure before the Company Announcement, provided further that the Executive first advises such persons not to reveal information about the Executive’s departure and each such person agrees. These
obligations shall not in any way affect any person’s obligations to provide truthful information as required by law. 
 8. Non-Disparagement. Subject to Section 13 of this Agreement, the Executive agrees not to take any action or make any statements (whether written, oral, through social or electronic media or otherwise)
that are disparaging about or adverse to the business interests of the U.S. Subsidiary, the Parent, any of the U.S. Subsidiary’s and the Parent’s respective affiliates, or any 

  
 5 

 
of the foregoing entities’ products, services or current or former officers, directors, shareholders, employees, managers or agents. Subject to Section 13 of this Agreement, the Parent
and the U.S. Subsidiary each agrees to instruct their senior executives and the senior executives of their respective affiliates not to take any action or make any statements (whether written, oral, through social or electronic media or otherwise)
that are disparaging about or adverse to the business interests of the Executive. These non-disparagement obligations shall not apply to truthful testimony in any legal proceeding. 

9. Waiver of English Statutory Claims. The Executive agrees that he will on or before the date of this Agreement enter into a settlement
agreement that validly waives the statutory claims under English law in the form of the agreement at Exhibit A of this Agreement against the U.S. Subsidiary, the Parent and any relevant subsidiary and satisfies the conditions regulating settlement
agreements and settlement contracts under English law contained in section 147 of the Equality Act and section 203(3) of the Employment Rights Act and in any other act or statutory instrument referred to in Exhibit A. The payment of the Severance
Benefits set forth in Section 3 of this Agreement is strictly conditional on the Executive signing the settlement agreement set forth at Exhibit A and obtaining advice on such settlement agreement from an independent legal adviser. 

10. Acknowledgements. The Executive acknowledges and agrees that he has been paid all wages, salary, bonuses, expense reimbursements and
any other amounts that he is owed by the Company, if any, through the date of this Agreement. The Executive also acknowledges that he has been paid his annual cash incentive compensation for work performed in 2019 and is not owed any further
compensation from the Company except as explicitly set forth in this Agreement. 
 11. Continuing Obligations; Termination of Payments; Injunctive
Relief. The Executive acknowledges that his right to the Severance Benefits is conditioned on his full compliance with the provisions in Section 8 of the Employment Agreement, the Employee Confidentiality, Assignment and Noncompetition
signed by the Executive in connection with the Employment Agreement (the “Restrictive Covenants Agreement”), and Sections 6 - 9 of this Agreement (collectively, the “Continuing Obligations”). In the event that the Executive fails
to comply with any of the Continuing Obligations, in addition to any other legal or equitable remedies it may have for such breach, the Company shall have the right to terminate the Severance Benefits; provided that the right to terminate the
Severance Benefits shall not apply to an inadvertent breach of Section 6 that is cured by Executive upon notice of such breach. Such termination in the event of a breach by the Executive shall not affect the general release in Section 5 or
the Executive’s obligation to comply with the Continuing Obligations and shall be in addition to, and not in lieu of, the Company’s rights to other legal and equitable remedies that the Company may have. Further, Executive agrees that it
would be difficult to measure any harm caused to the Company that might result from any breach by the Executive of any of the Continuing Obligations and that, in any event, money damages would be an inadequate remedy for any such breach.
Accordingly, Executive agrees that if he breaches, or proposes to breach, any portion of the Continuing Obligations, the Company shall be entitled, in addition to all other remedies it may have, to seek an injunction or other appropriate equitable
relief to restrain any such breach, without showing or proving any actual damage to the Company and without the necessity of posting a bond. In the event of any litigation involving an alleged breach by Executive of any of such obligations, the
prevailing party shall be entitled to recover its attorney’s fees. 

  
 6 

 12. Advice of Counsel. This Agreement is a legally binding document and the Executive’s
signature will commit the Executive to its terms. The Executive acknowledges that he has been advised to discuss all aspects of this Agreement with his attorney, that he has carefully read and fully understands all of the provisions of this
Agreement and that he is voluntarily entering into this Agreement. In signing this Agreement, the Executive is not relying upon any promises or representations made by anyone at or on behalf of the Company. 

13. Protected Disclosures. Nothing in this Agreement or otherwise limits any person’s: (i) obligation to testify truthfully in any
legal proceeding; (ii) right to file a charge or complaint with any federal agency (such as the Equal Employment Opportunity Commission) or any state or local governmental agency or commission (together, a “Government Agency”); or
(iii) ability to communicate with any Government Agency or otherwise participate in any investigation or proceeding that may be conducted by any Government Agency. If the Executive files any charge or complaint with any Government Agency and if
the Government Agency pursues any claim on the Executive’s behalf, or if any other third party pursues any claim on the Executive’s behalf, the Executive waives any right to monetary or other individualized relief (either individually or
as part of any collective or class action); provided that nothing in this Agreement limits any right the Executive may have to receive a whistleblower award or bounty for information provided to the Securities and Exchange Commission. 

14. Time for Consideration; Effective Date. The Executive acknowledges that he has been given the opportunity to consider this Agreement for twenty-one (21) days from his receipt of this Agreement before signing it (the “Consideration Period”). To accept this Agreement, the Executive must return a signed, unmodified original or PDF copy of
this Agreement so that it is received by the undersigned on or before the expiration of the Consideration Period. If the Executive signs this Agreement prior to the end of the Consideration Period, the Executive acknowledges by signing this
Agreement that such decision was entirely voluntary and that he had the opportunity to consider this Agreement for the entire Consideration Period. The Executive and the Company agree that any changes or modifications to this Agreement shall not
restart the Consideration Period. For a period of seven (7) days from the date of his execution of this Agreement, the Executive shall retain the right to revoke this Agreement by written notice that must be received by the undersigned before
the end of such revocation period. This Agreement shall become effective on the business day immediately following the expiration of the revocation period (the “Effective Date”), provided that the Executive does not revoke this Agreement
during the revocation period. Notwithstanding the foregoing, the Company may withdraw the offer of this Agreement or may void this Agreement before the Effective Date if the Executive breaches any provision contained in this Agreement (including any
provision of the Restrictive Covenants Agreement). 
 15. Enforceability. The Executive acknowledges that, if any portion or provision of this
Agreement or the Continuing Obligations shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder other than those as to which it is so declared illegal or unenforceable, shall not be affected
thereby, and each portion and provision shall be valid and enforceable to the fullest extent permitted by law.  

  
 7 

 16. Entire Agreement. This Agreement along with the Continuing Obligations (including the
Restrictive Covenants Agreement) constitute the entire agreement between the Executive and the Company concerning the Executive’s relationship with the Company, and supersedes and replaces any and all prior agreements and understandings between
the Parties concerning the Executive’s relationship with the Company including, without limitation, the unpreserved provisions of the Employment Agreement, provided that the Equity Documents shall continue to be in full force and effect in
accordance with their terms, subject to Section 4 of this Agreement. In addition, and notwithstanding the foregoing, (i) Section 6 of the Employment Agreement shall remain in full force and effect for the three (3) months
following the Date of Termination to the extent consistent with the terms of this Agreement; and (ii) any obligation of the Company to indemnify the Executive against third party claims, including any obligation to advance expenses, pursuant to
the governing instruments of the Company or otherwise, shall remain in effect. 
 17. Waiver; Amendment. No waiver of any provision of this
Agreement, including the Continuing Obligations, shall be effective unless made in writing and signed by the waiving party. The failure of any Party to require the performance of any term or obligation of this Agreement or the Continuing
Obligations, or the waiver by any Party of any breach of this Agreement or the Continuing Obligations shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach. This Agreement may not be
modified or amended except in a writing signed by both the Executive and the Chairman of the Board. 
 18. Taxes. The Company shall undertake
to make deductions, withholdings and tax reports with respect to payments and benefits under this Agreement and in connection with other compensation matters to the extent that it reasonably and in good faith determines that it is required to make
such deductions, withholdings and tax reports. Payments under this Agreement shall be in amounts net of any such deductions or withholdings. Nothing in this Agreement shall be construed to require the Company to make any payments to compensate the
Executive for any adverse tax effect associated with any payments or benefits made to the Executive in connection with the Executive’s employment with the Company. 

19. Acknowledgment of Wage and Other Payments. The Executive acknowledges and represents that, except as expressly provided in this Agreement,
the Executive has been paid all wages, bonuses, compensation, benefits and other amounts that any of the Releasees has ever owed to the Executive. The Executive is not entitled to any bonus, incentive compensation or other compensation except as
specifically set forth in this Agreement. 
 20. Jurisdiction. The Parties agree that the state and federal courts of the Commonwealth of
Massachusetts shall have the exclusive jurisdiction to consider any matters related to this Agreement, including without limitation any claim of a violation of this Agreement. With respect to any such court action, the Executive submits to the
jurisdiction of such courts and acknowledges that venue in such courts is proper. 
 21. Governing Law; Interpretation. This Agreement shall be
interpreted and enforced under the laws of the Commonwealth of Massachusetts without regard to conflict of law principles. In the event of any dispute, this Agreement is intended by the Parties to be construed as a whole, to be interpreted in
accordance with its fair meaning, and not to be construed strictly for or against either Party or the “drafter” of all or any portion of this Agreement. 

  
 8 

 22. Counterparts. This Agreement may be executed in any number of counterparts, each of which
when so executed and delivered shall be taken to be an original, but all of which together shall constitute one and the same document. Facsimile and pdf signatures shall be deemed to be of equal force and effect as originals. 

[Remainder of page intentionally left blank.] 

  
 9 

 IN WITNESS WHEREOF, the Parties, intending to be legally bound, have executed this
Agreement on the date(s) indicated below. 
  

			
	PARENT
	
	ORCHARD THERAPEUTICS PLC
		
	By:	 	 /s/ John Ilett

	Name: John Ilett
	Title: Chief of Staff, Chief Legal Officer and Secretary
	
	Date: 17 March 2020
	
	U.S. SUBSIDIARY
	
	ORCHARD THERAPEUTICS NORTH AMERICA
		
	By:	 	 /s/ Frank Thomas

	Name: Frank Thomas
	Title: Chief Operating Officer & Chief Financial Officer
	
	Date: 17 March 2020
	
	EXECUTIVE
	
	 /s/ Mark Rothera

	Mark Rothera
	
	Date: 17 March 2020

  
 10 

 EXHIBIT A 

Settlement Agreement 

  
 11EX-10.2

 Exhibit 10.2 
  

			
	DATED	  	17 MARCH 2020

  

	(1)	 MARK ROTHERA 

  

	(2)	 ORCHARD THERAPEUTICS PLC 

 

	(3)	 ORCHARD THERAPEUTICS (EUROPE) LIMITED 

 

	(4)	 ORCHARD THERAPEUTICS NORTH AMERICA 

 
  

SETTLEMENT AGREEMENT 

WITHOUT PREJUDICE AND SUBJECT TO CONTRACT 
  

 
 5 Fleet Place
London EC4M 7RD 
 Tel: +44 (0)20 7203 5000 ● Fax: +44 (0)20 7203 0200
● DX: 19 London/Chancery Lane 
 www.charlesrussellspeechlys.com 

 CONTENTS 
  

					
	 1   DEFINITIONS
	  	 	1	 
		
	 2   THE COMPANY’S OBLIGATIONS
	  	 	2	 
		
	 3   YOUR OBLIGATIONS
	  	 	2	 
		
	 4   YOUR CLAIMS
	  	 	2	 
		
	 5   YOUR WARRANTIES
	  	 	2	 
		
	 6   SETTLEMENT
	  	 	3	 
		
	 7   MISCELLANEOUS
	  	 	4	 
		
	 SCHEDULE 1
	  	 	7	 
		
	 SCHEDULE 2
	  	 	9	 
		
	 SCHEDULE 3
	  	 	12	 
		
	 SCHEDULE 4
	  	 	13	 

  

 THIS AGREEMENT is made the 17th day
of March 2020 
 BETWEEN: 
  

	(1)	 MARK ROTHERA of
..............................................................................(you); 

 

	(2)	 ORCHARD THERAPEUTICS PLC of 108 Cannon Street, London, United Kingdom, EC4N 6EU (the Company);

  

	(3)	 ORCHARD THERAPEUTICS (EUROPE) LIMITED of 108 Cannon Street, London, United Kingdom, EC4N 6EU (the UK
Subsidiary); and 

  

	(4)	 ORCHARD THERAPEUTICS NORTH AMERICA of 101 Seaport Boulevard, 7th Floor, Boston, MA 02210 United States
(the US Subsidiary) 

 BACKGROUND 
  

	(A)	 You have been employed by the Company and the US Subsidiary since 12 June 2017 most recently as President
and Chief Executive Officer and have held associated offices with the companies. You have also been a statutory director of the UK Subsidiary since 4 September 2017. 

 

	(B)	 You have agreed to the mutual termination of termination of your employment with the Company and US Subsidiary
under the terms of a Separation Agreement and Release dated the same date as this Agreement (the US Agreement). In consideration for payments and benefits set out in the US Agreement, you have agreed to enter into this Agreement.

  

	(C)	 The parties have entered into this Agreement to record and implement the terms on which you have agreed to
settle any claims which you have or may have in connection with your Employment or its termination or otherwise against any Group Company or any of the Protected Parties whether or not those claims are, or could be, in the contemplation of the
parties at the time of signing this Agreement, and including, in particular any Statutory Claims which you have raised and/or raise in this Agreement. 

  

	(D)	 The parties intend this Agreement to be an effective waiver of any such claims and to satisfy the conditions in
relation to settlement agreements in the relevant legislation. 

  

	(E)	 These recitals are intended to be binding and form part of the Agreement. 

IT IS AGREED as follows: 
  

	1	 DEFINITIONS 

  

	1.1	 In this Agreement the definitions and interpretations set out in Schedule 1 apply (unless otherwise
stated). 

  
 1 

	2	 THE COMPANY’S OBLIGATIONS  

Legal costs 
  

	2.1	 The Company will make a contribution towards your reasonable legal costs incurred in taking advice on the terms
of this Agreement, up to a maximum of £1,000 (plus VAT), provided that: 

  

	 	2.1.1	 the Agreement is signed and completed by both parties; and 

 

	 	2.1.2	 the fees relate only to advice concerning the termination of your employment and the terms of this Agreement;
and 

  

	 	2.1.3	 the Solicitor signs and delivers to the Company the Certificate, 

in which case the fees will be paid directly to the Solicitor within 30 days of the Company receiving a copy of an invoice addressed to you,
showing the fees due and marked as being payable by the Company. The invoice should be marked “Private and Confidential, Addressee Only” and should be sent to the Nominated Person at
john.ilett@orchard-tx.com. 
  

	3	 YOUR OBLIGATIONS 

Resignation of Directorship 
  

	3.1	 You will resign with immediate effect from your directorships with the Group Companies registered with
Companies House in the United Kingdom by virtue of your Employment by signing and dating letters of resignation in the form of the drafts attached at Schedule 3. 

 

	4	 YOUR CLAIMS 

  

	4.1	 In the circumstances, you allege that, in addition to common law and contractual claims, you have or will have
the following claims arising from your Employment and/or its termination (together the Particular Claims): 

  

	 	4.1.1	 for wrongful dismissal; and 

 

	 	4.1.2	 for unfair dismissal, under section 111 of the Employment Rights Act 1996. 

 

	5	 YOUR WARRANTIES 

In relation to Statutory Claims 
  

	5.1	 You warrant that you have instructed the Solicitor to advise on whether you have or may have the Particular
Claims, any of the claims listed in Schedule 2 and/or any other Statutory Claims against the Protected Parties arising out of or in connection with the Issue, your Employment or the termination of your Employment and offices and the
matters envisaged by this Agreement and you have provided the Solicitor with all relevant information. 

  
 2 

	5.2	 You further warrant that, having received the Solicitor’s advice, you have the Particular Claims and no
other Statutory Claims against the Protected Parties, and that you are not aware of any facts or circumstances which may give rise to any other claims against the Protected Parties. 

 

	5.3	 You acknowledge that the Company acted in reliance on these warranties when entering into this Agreement.

 General 
 You warrant that other
than the matters expressly notified to the Company as at the date of this Agreement: 
  

	5.4	 To the best of your knowledge you have not committed any breach of duty (including fiduciary duty) owed to any
Group Company; 

  

	5.5	 To the best of your knowledge you have not done or omitted to do anything which: 

 

	 	5.5.1	 had the Company been aware of it, would have entitled the Company to terminate your employment summarily and
without compensation (if you had still been employed); or 

  

	 	5.5.2	 had it been done after the date of this Agreement would be in breach of the terms of this Agreement;

  

	5.6	 you are not employed, engaged or doing any work in any capacity, you are not in discussions which are likely to
lead to employment or engagement in any capacity and you have not received an offer to do any work, in any capacity; 

  

	5.7	 you are not aware of any circumstances or symptoms that may give rise to a claim by you against any Group
Company for personal injury or industrial disease or in respect of accrued pension rights; 

  

	5.8	 you agree that all and any grievances or complaints you have raised are hereby withdrawn and agree not to raise
a new grievance with the Company in the future. 

  

	6	 SETTLEMENT 

  

	6.1	 You accept the terms of the US Agreement and this Agreement in full and final settlement of all and any claims,
demands, costs and expenses or rights of action of any kind whether past, present or future (and whether such claims are known or unknown to the parties and whether contemplated or not) that you have or may have against the Protected Parties
relating directly or indirectly to your Employment, the Issue, the Particular Claims, the Employment Contract, directorships or other offices, the termination of any of them, any bonus, incentive, share/stock options, remuneration or other right,
expectation or entitlement arising by virtue of your Employment or the Employment Contract or any other matter, including any common law, contractual, tortious or Statutory Claims or any stress related claims or any claims relating to depression or
for physical or psychiatric illness relating to any acts of discrimination or any claim under European law. 

  
 3 

	6.2	 The waiver in clause 6.1 shall not apply to: 

 

	 	6.2.1	 any claim for enforcement of this Agreement and/or the Separation Agreement and Release; 

 

	 	6.2.2	 claims in respect of personal injury of which you are not aware and could not reasonably be expected to be
aware at the date of this Agreement (other than claims under the discrimination legislation); 

  

	 	6.2.3	 any claims in relation to accrued pension entitlements. 

 

	6.3	 You accept that the Company is entering into this settlement for the benefit of itself and, as trustee for each
of the other Protected Parties. 

  

	6.4	 You agree not to institute or pursue any claim in respect of any matter referred to in clause 4, any other
Statutory Claim or any other claim referred to in clause 6.1. 

  

	6.5	 If you breach any material provision of this Agreement or pursue a claim against any Group Company arising out
of your Employment or its termination other than those excluded under clause 6.2, you agree to indemnify the Company for any losses suffered as a result thereof, including all reasonable legal and professional fees incurred. 

 

	6.6	 This Agreement complies with and is intended to comply with the conditions regulating settlement agreements
under the requirements of each of the following (as amended): the Trade Union and Labour Relations (Consolidation) Act 1992; the Employment Rights Act 1996; the National Minimum Wage Act 1998; the Working Time Regulations 1998; the Trans-national
Information and Consultation of Employees Regulations 1999; the Part-time Workers (Prevention of Less Favourable Treatment) Regulations 2000; the Fixed-term Employees (Prevention of Less Favourable Treatment) Regulations 2002; the Information and
Consultation of Employees Regulations 2004; the Occupational and Personal Pension Schemes (Consultation by Employers and Miscellaneous Amendment) Regulations 2006; the Companies (Cross-Border Merger) Regulations 2007; the Pensions Act 2008; the
Equality Act 2010. 

  

	6.7	 You confirm that you have received independent legal advice from the Solicitor on the terms and effect of this
Agreement, and in particular its effect on your ability to pursue your rights before an Employment Tribunal. The Solicitor has confirmed to you that there is in force a contract of insurance or an indemnity provided for members of a profession
covering the risk of a claim against the Solicitor and/or the firm in respect of loss arising in consequence of the advice given to you. 

  

	7	 MISCELLANEOUS 

Binding Agreement 
  

	7.1	 You warrant that neither you nor any person acting on your behalf has manually or electronically amended any
draft of this Agreement provided to you by the Company, except where the Company has been made aware of such amendment in writing. 

  
 4 

	7.2	 This Agreement, whilst marked “Without Prejudice and Subject to Contract” will be binding upon the
parties upon completion. 

 Governing law and jurisdiction 

 

	7.3	 This Agreement is governed by the law of England and Wales and any dispute between the parties relating to it
is subject to the exclusive jurisdiction of the courts of England and Wales. 

 Contracts (Rights of Third Parties) Act 1999 

 

	7.4	 The Company enters into this Agreement for itself and as agent and trustee for all Protected Parties and is
authorised to do so. It is the parties’ intention that each of the Protected Parties should be able to enforce any rights conferred upon it under this Agreement, subject to and in accordance with the Contracts (Rights of Third Parties) Act
1999. No other person or entity which is not party to this Agreement shall have any rights under this Agreement under the Contracts (Rights of Third Parties) Act 1999 or otherwise. 

 

	7.5	 The consent of a third party shall not be required for the variation or termination of this Agreement, even if
that variation or termination affects the benefits conferred in this Agreement on that third party. 

 Assistance 

 

	7.6	 Subject always to any obligations owed by you to any third party, you agree to provide the Company with such
assistance as it may reasonably require prior to or following the Termination Date in the conduct of such complaints, investigations or proceedings as may arise in respect of which the Company or its legal advisors reasonably believes you may be
able to provide assistance and the Company will prior to your rendering such assistance agree with you the basis upon which it will reimburse you fairly for your time and effort should any such assistance require more than 2 business days of your
time, and pay your reasonable expenses incurred in providing such assistance. 

 Counterparts 

 

	7.7	 This Agreement may be executed in any number of counterparts, each of which, when executed, shall constitute a
duplicate original, but all the counterparts shall together constitute the one agreement. 

  
 5 

 Signed on the date set out at the commencement of this Agreement 

 

					
	SIGNED by JOHN ILETT for and on behalf of ORCHARD THERAPEUTICS PLC 	  	 )

)
	  	/s/ John Ilett
		  		  	  

  

					
	SIGNED by JOHN ILETT for and on behalf of: ORCHARD THERAPEUTICS (EUROPE) LIMITED	  	 )

)
	  	/s/ John Ilett
		  		  	  

  

					
	SIGNED by FRANK THOMAS for and on behalf of: ORCHARD THERAPEUTICS NORTH AMERICA	  	 )

)
	  	/s/ Frank Thomas
		  		  	  

  

					
	 SIGNED by MARK ROTHERA
	  	 )

)
	  	/s/ Mark Rothera
		  		  	  

  
 6 

 SCHEDULE 1 

Definitions and Interpretations 
  

	1	 DEFINITIONS 

 

			
	Certificate	  	the certificate at Schedule 3 of this Agreement to be signed and dated by the Solicitor
		
	Employment	  	your employment by any Group Company
		
	Employment Agreement	  	means the employment agreement between you and the Parent dated 12 June 2017, as amended
		
	Group Company	  	 the Company, the UK Subsidiary and US Subsidiary and any person, firm, company, business entity or other organisation;

 
 (a) which is directly or indirectly controlled by the Company.

 
 (b) which directly or indirectly controls the Company;

 
 (c) which is directly or indirectly controlled by a third party which also controls the
Company; or
  
 (d) of which the Company or any person, firm, company, business entity
or other organisation referred to in this definition of “Group” is a partner;
  

(e) of which the Company or any Group Company referred to in this definition of “Group” owns or has a beneficial interest (whether directly or
indirectly) in 20% or more of the issued share capital or 20% or more of the capital assets

		
	Nominated Person	  	John Ilett or such other person or persons nominated by the Company from time to time
		
	Protected Parties    	  	each of any Group Company and their respective officers, employees, workers, consultants, partners, members, shareholders or agents

  
 7 

			
	Solicitor	  	Peter L. Talibart of Seyfarth Shaw U.K. LLP, a firm of solicitors whose address is One RopeMaker Street, London EC2Y 9AW
		
	Statutory Claims	  	any claim referred to in the Health and Safety at Work Act 1974; the Trade Union and Labour Relations (Consolidation) Act 1992; the Employment Rights Act 1996; the Protection from Harassment Act 1997; the National Minimum Wage Act
1998; the Working Time Regulations 1998; the Public Interest Disclosure Act 1998; the Data Protection Act 1998; the Human Rights Act 1998; the Trans-national Information and Consultation of Employees Regulations 1999; the Maternity and Parental
Leave Regulations 1999; the Part-time Workers (Prevention of Less Favourable Treatment) Regulations 2000 and the Fixed-term Employees (Prevention of Less Favourable Treatment) Regulations 2002; the Employment Act 2002; the Information and
Consultation of Employees Regulations 2004, the Transfer of Undertakings (Protection of Employment) Regulations 2006; the Occupational and Personal Pension Schemes (Consultation by Employers and Miscellaneous Amendment) Regulations 2006; the
Employment Act 2008; the Pensions Act 2008; the Equality Act 2010; the Agency Workers Regulations 2010; the Enterprise and Regulatory Reform Act 2013; the General Data Protection Regulation(2016/679); the Data Protection Act 2018 and any claims from
which an employee may contract out by means of a settlement agreement

  

	2	 INTERPRETATIONS 

 

	2.1	 The headings in this Agreement are inserted for convenience only and shall not affect its construction.

  

	2.2	 A reference to a particular law is a reference to it as it is in force for the time being taking account of any
amendment, extension, or re-enactment and includes any subordinate legislation for the time being in force made under it. 

 

	2.3	 The schedules to this Agreement form part of (and are incorporated into) this Agreement. 

  
 8 

 SCHEDULE 2 

Employment Claims 
  

	1	 for breach of contract and/or wrongful dismissal; 

 

	2	 for unfair dismissal, under section 111 of the Employment Rights Act 1996; 

 

	3	 in relation to the right to a written statement of reasons for dismissal, under section 93 of the Employment
Rights Act 1996; 

  

	4	 in relation to unlawful detriment, under section 48 of the Employment Rights Act 1996, or section 56 of the
Pensions Act 2008; 

  

	5	 for a statutory redundancy payment, under section 163 of the Employment Rights Act 1996; 

 

	6	 in relation to an unlawful deduction from wages, under section 23 of the Employment Rights Act 1996;

  

	7	 in relation to written employment particulars and itemised pay statements, under section 11 of the Employment
Rights Act 1996; 

  

	8	 in relation to guarantee payments, under section 34 of the Employment Rights Act 1996; 

 

	9	 in relation to suspension from work, under section 70 of the Employment Rights Act 1996; 

 

	10	 in relation to parental leave, under section 80 of the Employment Rights Act 1996; 

 

	11	 in relation to a request for flexible working, under section 80H of the Employment Rights Act 1996;

  

	12	 in relation to time off work, under sections 51, 54, 57, 57B, 60, 63 and 63C of the Employment Rights Act 1996;

  

	13	 for pregnancy or maternity discrimination, direct or indirect discrimination, harassment or victimisation
because of and/or related to sex, marital or civil partnership status, pregnancy or maternity or gender reassignment under section 120 of the Equality Act 2010; 

 

	14	 for direct or indirect discrimination, harassment or victimisation because of and/or related to race under
section 120 of the Equality Act 2010; 

  

	15	 for direct or indirect discrimination, harassment or victimisation because of and/or related to disability,
discrimination arising from disability or failure to make reasonable adjustments under section 120 of the Equality Act 2010; 

  

	16	 for direct or indirect discrimination, harassment or victimisation because of and/or related to sexual
orientation under section 120 of the Equality Act 2010; 

  
 9 

	17	 for direct or indirect discrimination, harassment or victimisation because of and/or related to religion or
belief under section 120 of the Equality Act 2010; 

  

	18	 for direct or indirect discrimination, harassment or victimisation because of and/or related to age under
section 120 of the Equality Act 2010; 

  

	19	 for equal pay or equality of terms under sections 120 and 127 of the Equality Act 2010; 

 

	20	 in relation to the obligations to elect appropriate representatives or inform and consult or any entitlement to
a protective award, under the Trade Union and Labour Relations (Consolidation) Act 1992 (as amended); 

  

	21	 in relation to working time or holiday pay, under regulation 30 of the Working Time Regulations 1998;

  

	22	 in relation to the national minimum wage, under sections 11, 18, 19D and 24 of the National Minimum Wage Act
1998; 

  

	23	 in relation to the right to be accompanied, under section 11 of the Employment Relations Act 1999;

  

	24	 for less favourable treatment and/ or detriment on the grounds of being a part-time worker under regulation 8
of the Part-Time Workers (Prevention of Less Favourable Treatment) Regulations 2000 or otherwise; 

  

	25	 for less favourable treatment and/ or detriment on the grounds of being a fixed-term employee under regulation
7 of the Fixed-Term Employees (Prevention of Less Favourable Treatment) Regulations 2002 or otherwise; 

  

	26	 in relation to the obligations to elect appropriate representatives or inform and consult or any entitlement to
a protective award, under and/or concerning the Transfer of Undertaking (Protection of Employment) Regulations 2006 (as amended); 

  

	27	 for physical or psychiatric illness or injury (and all losses therefrom) relating to any acts of
discrimination; 

  

	28	 for any stress-related claims and/or any claims relating to depression or other mental illness and all losses
arising therefrom; 

  

	29	 in relation to any existing personal injury claims that you are aware of or should reasonably be aware of;

  

	30	 for breach of obligations under the Protection from Harassment Act 1997; 

 

	31	 under and/or concerning the Data Protection Act 1998, the Data Protection Act 2018 or the General Data
Protection Regulation 2016/679; 

  

	32	 under and/or concerning the Transnational Information and Consultation of Employees Regulations 1999;

  
 10 

	33	 under and/or concerning the Information and Consultation of Employees Regulations 2004; 

 

	34	 under and/or concerning the Occupational and Personal Pension Schemes (Consultation by Employers and
Miscellaneous Amendment) Regulations 2006; 

  

	35	 under and/or concerning the Human Rights Act 1998; 

 

	36	 in relation to refusal of employment, refusal of employment agency services and detriment under the Employment
Relations Act 1999 (Blacklists) Regulations 2010; 

  

	37	 in relation to time off for study or training under section 63I of the Employment Rights Act 1996;

  

	38	 in relation to the right to equal treatment, access to collective facilities and amenities, access to
employment vacancies and the rights not to be subjected to a detriment under regulations 5, 12, 13 and 17(2) of the Agency Workers Regulations 2010; 

  

	39	 arising as a consequence of the United Kingdom’s membership of the European Union. 

  
 11 

 SCHEDULE 3 

Certificate of Independent legal adviser 

I Peter Talibart of Seyfarth Shaw U.K.LLP whose address is Citypoint, One Ropemaker Street, London EC2Y 9AW confirm that I gave independent legal advice
to Mark Rothera (the Employee) as to the terms and effect of this Settlement Agreement and in particular its effect on the Employee’s ability to pursue any claims before an Employment Tribunal. 

I confirm that I am a solicitor of the Senior Courts of England & Wales holding a current practising certificate. Further, I confirm that there was
in force at the time I gave the advice a contract of insurance or an indemnity provided for members of a profession or professional bodies covering the risk of a claim by the Employee in respect of any loss arising from my advice. 

I confirm I am not acting (and have not acted) in relation to this matter for any Group Company as defined in the Agreement. 

Signed: /s/ Peter Talibart 
 Dated:    20
March 2020 

  
 12 

 SCHEDULE 4 

Resignation 
 The Directors 

Orchard Therapeutics PLC 
 108 Cannon Street 

London 
 EC4N 6EU 

United Kingdom 
 17 March 2020 

Dear Sirs 
 I hereby resign from my office as a director of
Orchard Therapeutics PLC with immediate effect, and I confirm that I have no claims against the Company arising from my resignation. 
  

	
	 Yours faithfully

	
	 /s/ Mark Rothera

	
	 Mark Rothera

  
 13 

 The Directors 

Orchard Therapeutics (Europe) Limited 
 108 Cannon Street 

London 
 EC4N 6EU 

United Kingdom 
 17 March 2020 

Dear Sirs 
 I hereby resign from my office as a director of
Orchard Therapeutics (Europe) Limited with immediate effect, and I confirm that I have no claims against the Company arising from my resignation. 
  

	
	 Yours faithfully

	
	 /s/ Mark Rothera

	
	 Mark Rothera

  
 14

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00306-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00306-of-00352.parquet"}]]